The estimated Net Worth of James J Marino is at least $955 Tisíc dollars as of 28 September 2021. Mr. Marino owns over 5,952 units of Celldex Therapeutics stock worth over $888,348 and over the last 9 years he sold CLDX stock worth over $0. In addition, he makes $67,144 as Independent Director at Celldex Therapeutics.
Sign up
Mr. Marino CLDX stock SEC Form 4 insiders trading
James has made over 9 trades of the Celldex Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 5,952 units of CLDX stock worth $24,998 on 28 September 2021.
The largest trade he's ever made was buying 150,000 units of Celldex Therapeutics stock on 25 November 2019 worth over $30,000. On average, James trades about 9,574 units every 64 days since 2016. As of 28 September 2021 he still owns at least 21,334 units of Celldex Therapeutics stock.
You can see the complete history of Mr. Marino stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Marino biography
James J. Marino Esq., J.D. serves as Independent Director of the Company. Mr. Marino has served as a member of the board of directors of Onconova Therapeutics, Inc., a publicly held biopharmaceutical company, since July 2015 and is currently a member of their Audit Committee and Chair of their Compensation Committee. Prior to July 2015, Mr. Marino was a Partner at the global law firm of Dechert LLP for 28 years, where he served as Managing Partner of the Princeton Office. Previously, he served on the board of directors of Pharmacopeia Inc. and has worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson University Hospital. He currently serves on the Board of Trustees of Wake Forest University and Wake Forest University Baptist Medical Center. Mr. Marino received his B.A., M.B.A., and J.D. from Rutgers University.
What is the salary of James Marino?
As the Independent Director of Celldex Therapeutics, the total compensation of James Marino at Celldex Therapeutics is $67,144. There are 15 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.
How old is James Marino?
James Marino is 70, he's been the Independent Director of Celldex Therapeutics since 2017. There are 3 older and 21 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.
What's James Marino's mailing address?
James's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.
Insiders trading at Celldex Therapeutics
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil a Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
What does Celldex Therapeutics do?
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
What does Celldex Therapeutics's logo look like?
Complete history of Mr. Marino stock trades at Celldex Therapeutics a Onconova Therapeutics Inc
Celldex Therapeutics executives and stock owners
Celldex Therapeutics executives and other stock owners filed with the SEC include:
-
Ronald Pepin,
Senior Vice President and Chief Business Officer -
Anthony Marucci,
President, Chief Executive Officer, Director -
Anthony S. Marucci M.B.A.,
Founder, Pres, CEO & Director -
Tibor Keler,
Executive Vice President and Chief Scientific Officer -
Dr. Tibor Keler,
Founder, Chief Scientific Officer & Exec. VP -
Dr. Diane C. Young M.D.,
Sr. VP & Chief Medical Officer -
Margo Heath-Chiozzi,
Senior Vice President - Regulatory Affairs -
Sam Martin,
Chief Financial Officer, Senior Vice President, Secretary -
Richard Wright,
Senior Vice President, Chief Commercial Officer -
Dr. Margo Heath-Chiozzi M.D.,
Sr. VP of Regulatory Affairs -
Elizabeth Crowley,
Senior Vice President, Chief Product Development Officer -
Sam Martin,
Sr. VP, CFO, Sec. & Treasurer -
Elizabeth Crowley,
Chief Product Devel. Officer & Sr. VP -
Karen Shoos,
Independent Chairman of the Board -
Keith Brownlie,
Independent Director -
James Marino,
Independent Director -
Harry Penner,
Independent Director -
Herbert Conrad,
Independent Director -
Diane Young,
Senior Vice President, Chief Medical Officer -
Sarah Cavanaugh,
Senior Vice President - Corporate Affairs and Administration -
Prof. Joseph P. Schlessinger Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Dr. Richard M. Wright Ph.D.,
Chief Commercial Officer & Sr. VP -
Dr. Ronald A. Pepin,
Chief Bus. Officer & Sr. VP -
Freddy A. Jimenez Esq.,
Sr. VP & Gen. Counsel -
Patrick Till,
Sr. Director of Investor Relations & Corp. Communications -
Sarah Cavanaugh,
Sr. VP of Corp. Affairs & Admin. -
Theresa La Vallee,
SVP, Reg.& Precision Medicine -
Larry Ellberger,
Director -
George Elston,
Director -
Gerald Ph D Mc Mahon,
Director -
Avery W Catlin,
Sr. VP & CFO -
Den Broek Richard Van,
Director -
Rita Jain,
-
Timothy M Shannon,
Director -
Rajesh B Parekh,
Director -
Charles R Schaller,
Director -
Inc Medarex,
10% owner -
Ronald C Newbold,
Sr. VP, Business Dev. -
Cheryl Cohen,
-
Freddy A. Jimenez,
SVP & GENERAL COUNSEL -
Garry Arthur Neil,